172 Results

People

  1. Motzer
    Motzer
  2. Abrey
    Abrey
  3. De Angelis
    De Angelis
  4. Riely
    Riely
  5. Abou-Alfa
    Abou-Alfa
  6. Kelly
    Kelly
  7. Scher
    Scher
  8. Drilon
    Drilon
  9. Feldman
    Feldman
  10. Ginsberg
    Ginsberg

Groups

  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)
  7. Biostatistics Service (27)
  8. Thoracic Oncology (19)
  9. Division of Subspecialty Medicine (18)
  10. GSK Faculty (18)
  1. "hypophosphatemia"
Formats
  1. Journal Article (160)
  2. Review (7)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)

More Groups

People
  1. Robert Motzer (18)
  2. Lauren Abrey (9)
  3. Lisa De Angelis (8)
  4. Gregory Riely (7)
  5. Ghassan Abou-Alfa (6)
  6. Howard Scher (6)

More People

Years
  1. 2025 (8)
  2. 2024 (13)
  3. 2023 (13)
  4. 2022 (7)
  5. 2021 (4)
  6. 2020 (21)

More Years

Publications
  1. Lancet Oncology (16)
  2. Cancer (11)
  3. Clinical Cancer Research (11)
  4. Journal of Clinical Oncology (10)
  5. New England Journal of Medicine (10)
  6. Neuro-Oncology (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (25)
  2. Elsevier Inc. (19)
  3. American Association for Cancer Research (12)
  4. Wiley Blackwell (12)
  5. Oxford University Press (11)
  6. Springer (11)

More Publishers

Results (172)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Journal Article

    Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study
    Journal Article

    Sequist, L. V.; Han, J. Y.; Ahn, M. J.; Cho, B. C.; Yu, H.; Kim, S. W.; Yang, J. C. H.; Lee, J. S.; Su, W. C.; Kowalski, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials
    Journal Article

    Drilon, A.; Siena, S.; Dziadziuszko, R.; Barlesi, F.; Krebs, M. G.; Shaw, A. T.; de Braud, F.; Rolfo, C.; Ahn, M. J.; Wolf, J.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials
    Journal Article

    Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A. T.; Farago, A. F.; Blakely, C. M.; Seto, T.; Cho, B. C.; Tosi, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • PD-1 blockade in advanced adrenocortical carcinoma
    Journal Article

    Raj, N.; Zheng, Y.; Kelly, V.; Katz, S. S.; Chou, J.; Do, R. K. G.; Capanu, M.; Zamarin, D.; Saltz, L. B.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Denosumab for giant cell tumour of bone: Success and limitations
    Editorial

    Healey, J. H.
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy
    Journal Article

    Munster, P.; Mita, M.; Mahipal, A.; Nemunaitis, J.; Massard, C.; Mikkelsen, T.; Cruz, C.; Paz-Ares, L.; Hidalgo, M.; Rathkopf, D.; more...
    Cancer Management and Research (2019)

    Fulltext@MSK | Save
  • Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: A pooled analysis
    Journal Article

    Antonia, S. J.; Borghaei, H.; Ramalingam, S. S.; Horn, L.; De Castro Carpeño, J.; Pluzanski, A.; Burgio, M. A.; Garassino, M.; Chow, L. Q. M.; Gettinger, S.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105
    Journal Article

    Drilon, A.; Fu, S.; Patel, M. R.; Fakih, M.; Wang, D.; Olszanski, A. J.; Morgensztern, D.; Liu, S. V.; Cho, B. C.; Bazhenova, L.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save